Gujarat Magazine

DelveInsight’s “Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Amyotrophic Lateral Sclerosis, historical and forecasted epidemiology as well as the Amyotrophic Lateral Sclerosis market trends in the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, Japan and China.

 

Key Takeaways from the Amyotrophic Lateral Sclerosis Market Research Report

• According to the estimates, in Japan, it is observed that ALS was most prevalent in the 70-79 years age group, followed by 60-69 years, and 50–59 years.
• The major sites of onset of ALS are the bulbar, and spinal, along with other uncertain regions. In 2023, the patients with the spinal as a site of onset accounted highest cases, i.e., 15,000, followed by the bulbar site of onset.
• The increase in Amyotrophic Lateral Sclerosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Amyotrophic Lateral Sclerosis Market is anticipated to witness growth at a considerable CAGR.
• The leading Amyotrophic Lateral Sclerosis Companies working in the market include Helixmith, Sanofi, Denali Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, and others.
• Promising Amyotrophic Lateral Sclerosis Pipeline Therapies in the various stages of development include BIIB067, FAB122, ABBV-CLS-7262, Trametinib, BIIB105, AstroRx, Dazucorilant, AP-101, RAPA-501, ION-363, Reldesemtiv, MN-166, RT001, Fasudil, SAR443820, PTC857, ANX005, DNL343, RNS60, BIIB100, CNMAu8, 18F-OP-801, Pegcetacoplan (APL-2), Cu(II)ATSM, KNS-760704, IFB-088, LAM-002A, CK 0803, 3K3A-APC, QRL-201, Dexpramipexole, AL001, PrimeC, BLZ945, AT-1501, and others.
• April 2024: Ionis Pharmaceuticals Inc.- A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS).
• April 2024:- MediciNova- A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis.

 

Discover which therapies are expected to grab the Amyotrophic Lateral Sclerosis Market Share @ Amyotrophic Lateral Sclerosis Market Outlook

 

Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and the spinal cord. The disease specifically impacts the neurons responsible for controlling voluntary muscle movement, which are known as motor neurons.

 

Amyotrophic Lateral Sclerosis Epidemiology Insights

The epidemiology section of Amyotrophic Lateral Sclerosis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

• Amyotrophic Lateral Sclerosis Prevalence
• Amyotrophic Lateral Sclerosis Diagnosed Prevalence
• Amyotrophic Lateral Sclerosis Gender-specific Distribution
• Amyotrophic Lateral Sclerosis Mutation-specific Distribution
• Amyotrophic Lateral Sclerosis Type-specific Distribution
• Amyotrophic Lateral Sclerosis Distribution based on Site of onset
• Amyotrophic Lateral Sclerosis Age-specific Distribution

 

Download the report to understand which factors are driving Amyotrophic Lateral Sclerosis Epidemiology trends @ Amyotrophic Lateral Sclerosis Epidemiological Insights

 

Amyotrophic Lateral Sclerosis Drugs Market

The Amyotrophic Lateral Sclerosis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Amyotrophic Lateral Sclerosis signaling in Amyotrophic Lateral Sclerosis are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Amyotrophic Lateral Sclerosis Treatment Market Landscape

The Amyotrophic Lateral Sclerosis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Amyotrophic Lateral Sclerosis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Amyotrophic Lateral Sclerosis treatment guidelines, visit @ Amyotrophic Lateral Sclerosis Treatment Market Landscape

 

Amyotrophic Lateral Sclerosis Market Outlook

The report’s outlook on the Amyotrophic Lateral Sclerosis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Amyotrophic Lateral Sclerosis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Amyotrophic Lateral Sclerosis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Amyotrophic Lateral Sclerosis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Amyotrophic Lateral Sclerosis Drugs Uptake

The drug chapter of the Amyotrophic Lateral Sclerosis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Amyotrophic Lateral Sclerosis.

 

Major Amyotrophic Lateral Sclerosis Companies

Several Amyotrophic Lateral Sclerosis Companies working in the market include Helixmith, Sanofi, Denali Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, and others.

 

Learn more about the FDA-approved drugs for Amyotrophic Lateral Sclerosis @ Drugs for Amyotrophic Lateral Sclerosis Treatment

 

Scope of the Amyotrophic Lateral Sclerosis Market Report

• Coverage- 7MM
• Amyotrophic Lateral Sclerosis Companies- Helixmith, Sanofi, Denali Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, and others.
• Amyotrophic Lateral Sclerosis Therapies- BIIB067, FAB122, ABBV-CLS-7262, Trametinib, BIIB105, AstroRx, Dazucorilant, AP-101, RAPA-501, ION-363, Reldesemtiv, MN-166, RT001, Fasudil, SAR443820, PTC857, ANX005, DNL343, RNS60, BIIB100, CNMAu8, 18F-OP-801, Pegcetacoplan (APL-2), Cu(II)ATSM, KNS-760704, IFB-088, LAM-002A, CK 0803, 3K3A-APC, QRL-201, Dexpramipexole, AL001, PrimeC, BLZ945, AT-1501, and others.
• Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis Market Drivers and Barriers
• Amyotrophic Lateral Sclerosis Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Amyotrophic Lateral Sclerosis Drugs in development @ Amyotrophic Lateral Sclerosis Clinical Trials Assessment

 

Table of Content

1. KEY INSIGHTS

2. REPORT INTRODUCTION

3. ALS MARKET OVERVIEW AT A GLANCE

4. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY

5. EXECUTIVE SUMMARY

6. KEY EVENTS

7. DISEASE BACKGROUND AND OVERVIEW

8. TREATMENT AND MANAGEMENT OF ALS

9. EPIDEMIOLOGY AND PATIENT POPULATION OF THE 7MM

10. PATIENT JOURNEY

11. KEY ENDPOINTS IN ALS

12. MARKETED DRUGS

13. EMERGING DRUGS

14. ALS: 7MM ANALYSIS

15. UNMET NEEDS

16. SWOT ANALYSIS

17. KOL VIEWS

18. MARKET ACCESS AND REIMBURSEMENT

19. APPENDIX

20. DELVEINSIGHT CAPABILITIES

21. DISCLAIMER

22. ABOUT DELVEINSIGHT 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/